Abstract

Introduction
Treatment of locally advanced vulva cancer (LAVC) remains challenging. Due to the lack of randomised trials many questions regarding the indications for different treatment options and their efficacy remain unanswered.
Methods
In this retrospective study we provide the largest published series of LAVC patients treated with anovulvectomy, reporting oncological outcomes and morbidity.
Additionally, a systematic literature review was performed for all treatment options 1946 -2015.
Results
In our case series, 57/70 (81%) patients were treated in the primary setting with anovulvectomy and 13 patients underwent anovulvectomy for recurrent disease. The median overall survival (OS) was 69 months (1-336) with disease specific survival of 159 months . Following anovulvectomy for primary disease, time to progression and OS were significantly higher in node negative disease (10 vs. 96 months; 19 vs. 121 months, p<0.0001). Post-surgical complications were observed in 36 (51.4%), the majority of which were Grade I/II infections. There was one perioperative death.
Review of the literature showed that chemotherapy, radiotherapy or combination treatments are alternatives to surgery. Evidence relating to all of these consisted mostly of small retrospective series, which varied considerably in terms of patient characteristics and treatment schedules. Significant patient and treatment heterogeneity prevented meta-analysis with significant biases in these studies. It was
Introduction
Surgery forms the cornerstone of management of vulval cancer. Approximately one third of vulval cancer patients present with locally advanced vulval cancer (LAVC) [1] , for which there is little consensus regarding its definition. We have defined LAVC as cancers which encroach upon or cross the borders with surrounding structures such as the urethra or anus. Interest in non-surgical alternative more conservative approaches for this subset of women stems from the recognised psychosexual sequelae and physical morbidity associated with radical surgical resection and in particular, the need for a stoma. There has been little progress made in the last 20 years in the development of guidance for treatment of LAVC and it should be acknowledged that the evidence to date for managing LAVC is entirely based on small phase II trials, uncontrolled studies or retrospective case series without matched controls. It is therefore difficult to group or compare patients owing to the significant heterogeneity in both the patient populations as well as variation in the treatment approach and the complicating factor that many patients treated by primary chemoradiation would have been considered unsuitable for surgery by numerous institutions. Modern medicine dictates the use of evidence-based medicine and in this review we collate the available evidence for surgical management as well as the alternative approaches of chemotherapy, radiotherapy and combination modalities.
In addition, we provide our institute's experience of the surgical management of locally advanced peri-anal tumours treated with anovulvectomy, which comprises the largest series from a single tertiary centre over 36 years and report the oncological outcomes and morbidity. Finally, we discuss the need and feasibility of a clinical trial to address many of the unanswered questions.
Methods
Case Series
A retrospective review of women, 1978 -2014, with LAVC treated by anovulvectomy at the Northern Gynaecological oncology Centre, UK was conducted. Data from operative records, pathology reports, medical records, the MDT database and death certificates were accessed in conjunction with morbidity data from the prospectively collected departmental database.
The staging workup for patients with LAVC is not standardised. In our institute all patients underwent examination under anaesthesia and preoperative imaging (MRI /CT, from 1990) to define extent of local tumour, lymph node status and presence of distant metastatic disease. PET has been introduced in more recent years to evaluate metastatic disease. In primary diagnosed cases, bilateral groin node dissection (BGND) was also performed. The operative procedure is described in Supplementary Box 1. [2] All vulval biopsies and excision specimens were reported as advised by the Royal College of Pathologists' Standards and datasets for reporting cancers [3] . The new FIGO staging (2009) was retrospectively determined in all cases predating the revised guidelines [4] . Follow-up was to the last date seen in the outpatient clinics, or last contact by patient or GP.
Primary oncological outcomes included time to progression and overall survival (OS). Univariate associations between these endpoints and other variables were examined using Chi 2 or Fisher's exact test, as appropriate. Secondary outcomes focused upon treatment-related morbidity. Peri-operative and long-term side-effect frequencies were reported. For OS, patients who died at follow-up (any cause) were considered uncensored, whereas patients alive at last follow-up, or lost to follow-up were censored. Univariate analyses for OS and PFS were generated by KaplanMeier survival curves and log-rank (Mantel-Cox) tests for statistical significance.
Systematic Literature Review
The aim of this systematic review was to assess the evidence for the impact of surgery, radiotherapy, chemotherapy, and combination chemoradiation treatments on survival in patients with histologically proven LAVC. The secondary objective was to assess associated morbidity with each of these treatment modalities including preservation of anus.
A systematic literature search was conducted in December 2015 using the PRISMA guidance [5] . MEDLINE (1946 MEDLINE ( to 2015 , EMBASE (1980 EMBASE ( to 2015 , Web of Science and relevant Cochrane registers were searched. Controlled vocabularies and key words that were related to "vulva* cancer*/carcinoma*/malignan*/neoplasm*", "anovulvectomy", "exenteration", "chemotherap*" and "radiotherap*/radiation" were used in a search strategy. In addition, hand searching the reference lists of previous related review articles was performed. Title/abstract screening, full-text review, data extraction, and quality assessment were performed. Data regarding the patient group, treatment modality regimen, secondary treatments and survival was extracted along with reported morbidity, where available. Articles without an available English translation and case studies of single patients were excluded. Both prospective and retrospective studies were included.
Results
Case Series
In the 36 year study period 70 patients underwent anovulvectomy for primary or recurrent LAVC. The median age of diagnosis was 69 years (30 -91) with 68/70 (97.1%) squamous cell carcinomas, one adenocarcinoma and one adenoid cystic carcinoma. 57/70 (81.4%) patients underwent anovulvectomy as primary treatment for histologically-proven vulval cancer, 56 of which underwent BGND. One patient with a Bartholin's gland SCC did not undergo lymphadenectomy.
Median length of follow-up for the entire cohort (primary and recurrent disease) was 39 months (0 -336 months). 19/70 (27.1%) patients received adjuvant treatment post-operatively; 17 of whom received groin radiotherapy for groin node metastases (+/-vulva radiotherapy for close resection margin(s)); one had chemotherapy, and one had combination chemo-radiation for extra-pelvic node metastases. Survival for all cases was not significantly associated with age, tumour size or resection margin. However, survival was positively associated with lymph node status and stage. As expected, prognosis was significantly worse in node positive disease in comparison to node negative disease, Figure 1 , Table 1 . Median time to progression in the node positive group was 10 months, in comparison to 96 months in the node negative group, log-rank, p<0.0001). Median OS was 19 months in node positive disease in comparison to 121 months in node negative disease, log-rank, p=0.0010, Figure 1 . elected to undergo prolapse surgery and there were three patients who reported symptoms resulting from the rectal stump. Of those that had died, 27 (67.5%) died of disease, and 13 died of other causes, the majority of which were secondary to advanced cardiological or respiratory co-morbid conditions.
Anovulvectomy for primary treatment of LAVC
Anovulvectomy for locally recurrent disease
The rate of complications observed in this series is low in comparison to similar case series treated with pelvic exenteration. In one exenteration case series, in which the indication for exenteration was primary LAVC in the majority, the authors report a mortality rate of 7%, of which intra-operative mortality accounted for 3.5% [6] . Additionally, with exenteration major complications occurred in 42.9%, with early complications including massive bleeding from the sacral plexus, adult respiratory distress syndrome, acute renal failure, ureteric imjury, re-operation and pulmonary embolus. This is further supported by several other reports in gynaecological series [7] [8] [9] .
Literature Review
191 articles were identified from the initial search for further evaluation. A majority were review articles published in oncology journals or case series with 43 studies included in the review. There were no randomised controlled trials (RCTs) directly comparing the different treatment modalities and no case controls in the studies included. The heterogeneity of articles and differences in definitions and outcomes made this unsuitable for a meta-analysis.
Radical Surgery (n=12 studies)
It is largely accepted that if it is possible to resect the primary tumour with clear surgical margins without damaging the urethra or anal sphincter leading to urinary or faecal incontinence, primary surgical excision is typically the preferred treatment.
When the disease involves the anus, rectum, rectovaginal septum, proximal urethra, or bladder, in order to obtain adequate surgical margin, some form of pelvic exenteration may be required necessitating permanent colostomy and/or urinary diversion and therefore may only be appropriate in carefully selected cases. Since the 1970s pelvic exenteration has been repeatedly discussed and evaluated in small studies [10] [11] [12] , with variable oncological outcomes and varying degrees of associated morbidity [13, 14] , Table 2 . Historically, 5-year survival after pelvic exenteration for vulval cancer has been reported around 50%, but, survival is related to lymph node status, with a poor prognosis when groin lymph nodes are found to be positive [15] [16] [17] [18] .
As alternatives to exenteration there have been several published series, including a series by Hoffman et al who described the use of radical local excision (complete anal resection without colostomy, anal resection with partial resection of the sphincter, and partial removal of the anal skin) [19] . This however resulted in faecal incontinence in 100% of the first group, 50% of the second and 11% of the third.
Adams et al reported on the use of proctectomy combined with vulvectomy and BGND in a small series of five patients [20] . This was a single-step procedure, with stapling of the rectum and creation of a transverse colostomy and mucus fistula. It was not possible to comment on long-term survival as only 3/5 patients were alive and free of disease after a relatively short period of follow-up. A small series from our own institution (n=23) [21] , which has been included in the case series in this review, reports the use of anovulvectomy for LAVC. This approach offers a treatment with good survival outcomes and with relatively low morbidity.
When considering all radical surgery collectively, surgery has a reported postoperative mortality rate ranging from 0% to 20%, with a mean of about 4% [1] .
Psychological morbidity can also be considerable but there is a lack of robust published evidence to quantitate or assess it directly. Sexual impact of vulvectomy has not been assessed however, a systematic review and meta-analysis on quality of life after surgery for rectal cancer, found no significant differences in quality of life in rectal cancer patients with a permanent stoma when compared to non-stoma patients [22, 23] . No similar data is available for LAVC.
Overall when considering all surgical approaches, including exenteration as well as our series of anovulvectomy, surgical excision has been shown to result in good survival outcomes. The cumulative disease-free survival is reported at 46% overall and as with early stage vulval cancer, prognosis correlates well with lymph node status [1] . This is frequently at the cost of performing a stoma but data reporting the physical and psychological consequences of this is lacking.
Reconstructive surgery
A full discussion of reconstructive surgery following radical excision of LAVC is out with the scope of this review but it should be acknowledged that reconstructive options includes skin grafting as well as the use of flaps. Skin grafting is challenging in this area as it is difficult to avoid shearing forces and infection with delayed healing or graft loss being common [24] . Contractures can also be problematic, interfering with functions such as urination and intercourse [25] . Additionally, if patients have previously received local radiotherapy, reconstructive surgery is more challenging and may be associated with higher rates of morbidity. There is a lack of evidence comparing primary/secondary closure with reconstructive surgery.
Neoadjuvant radiotherapy (n=5 studies)
Over the last 2 decades, the use of primary radiotherapy (RT) for patients with stage III-IVA vulval cancer increased from 18% in 1988 to 30% by 2008 [26] . Boronow et al first reported neoadjuvant RT followed by surgical resection as an alternative to pelvic exenteration in 1982 [27] . In this series of 48 patients, 77% received preoperative RT followed by radical vulvectomy. No residual disease was identified in 42.5% of surgical specimens and exenteration was performed in four cases. The 5-year survival rates were 75.6% for the primary cases, 62.6% for the recurrent cases, and an overall 72% for all 48 cases treated. Hacker et al published similar findings in eight patients treated with preoperative RT with satisfactory shrinkage of tumour in 87.5%, [28] . However, in the series of 16 patients, 11 of which had perianal disease, treatment by RT to the vulva, inguinal and pelvic nodes, followed by radical vulvectomy and lymphadenectomy, failed in 6 (37.5%) patients, necessitating colostomy formation [29] . Despite macroscopic excision margins of 2 cm, 5/14 showed microscopic disease within 1 cm of the margin, three of which later developed local recurrence and a further 25% of patients developed central recurrence disease.
Although the data are limited, it appears that preoperative RT alone (45-54 Gy EBRT ± 24 Gy brachytherapy) may downsize of the tumour in 70% -85% of patients, reducing the need for exenterative surgery. This is unavoidable in some, see Table   3 . Additionally, this approach is also associated with significant morbidity. Following neoadjuvant RT, surgery and subsequent healing may be compromised by poor local blood supply and lymphatic drainage. Radiotherapy also carries risks of skin desquamation, wound cellulitis with subsequent prolonged hospitalisation, bowel and bladder toxicity and contractures. Furthermore, a temporary bowel diversion may be required for patients to be able to tolerate and complete a course of radiation therapy. Even with combined therapy, 50-70% of advanced stages may recur [30] .
Further data upon short and long-term morbidity as well as survival are needed.
Based upon a reasonably good response rate from these series, further investigation of this modality appears warranted especially in groin node positive cases where radiotherapy to the groins may be given simultaneously and where the long term prospects appear to be poor with all of the treatment options.
Neoadjuvant chemotherapy (n=5 studies)
Different chemotherapy regimens have been used in LAVC with varying degrees of success, Table 4 . All of the studies suggest that vulval cancer responds to chemotherapy to a variable extent and there is evidence that some cancers can be rendered more operable. In an EORTC Phase II study of neoadjuvant treatment with triple combination therapy (Bleomycin, methotrexate and lomustine) complete response was seen in only 8%, and partial response in 48% [31] . The 1 year survival was only 32% and this regimen was associated with major haematological side effects and mild signs of bleomycin-related pulmonary toxicity. In another series of 21 stage IV patients, Benedetti-Panici, et al reported partial response in the size of the primary tumour in two patients and partial/complete response in the inguinal node disease in 14 patients [32] . All patients required radical vulvectomy but the therapeutic results were poor with a 3-year survival of 24%. Sixty-eight percent of the operated patients recurred 3-17 months from the end of treatment and 50% of them had a distant relapse.
Giesler et al showed no clinical response with cisplatin alone but partial clinical response following combination treatment with cisplatin and 5-FU [33] . All patients underwent radical vulvectomy following NACT and the anal sphincter and urethra were conserved in all patients receiving combination chemotherapy.
Recurrence remains a problem even after successful surgical removal of residual disease with 20/27 patients who completed treatment with NACT followed by surgery developing local/nodal recurrences in one study [34] . Toxicity of chemotherapy may also be problematic with severe haematological toxicity and gastro-intestinal toxicity all being well documented.
Overall, the role of neoadjuvant chemotherapy appears limited but may serve a role in those cases unsuitable for surgery or radiotherapy treatments, in those with distant disease or in the palliative setting in select cases.
Concurrent chemoradiation with or without subsequent surgery (n=19 studies)
The addition of chemotherapy concurrent with RT for LAVC was influenced by advances in the treatment of anal squamous cell carcinomas, which showed improved local control and colostomy-free survival with the addition of fluorouracil (5-FU) and mitomycin C [35, 36] . Several small studies have assessed the feasibility and activity of concomitant chemoradiation in a neoadjuvant setting followed by tailored surgery for LAVC with a variety of regimens and agents used, Table 5 .
The combination of bleomycin and RT was disappointing [37, 38] Despite these findings, a Cochrane review of five series concluded that the combination of chemoradiation and radical surgery is associated with significantly more morbidity than either treatment given on its own [58] . The combination of 5-FU and mitomycin C is associated with high rates of toxicity and subsequently this regimen has not been used in the newer chemoradiation studies in other cancer types. Skin and subcutaneous atrophy is common and wound breakdown occurs in 20-31% of the patients [25] . Severe complications can include bowel perforation, bowel obstruction, avascular hip necrosis, and toxic deaths. Surgical interventions after chemoradiation have high complication rates and the impact of tumour bed resection in cases of complete remission is unclear [24] . Additionally, acute toxicities may necessitate radiotherapy interruptions and dose modifications, compromising its treatment effect [59] .
Collectively available studies have demonstrated that pre-operative combination chemoradiation is feasible and may reduce the need for more radical surgery.
However, this is at a cost of a lower local control rate compared with primary surgery.
Concurrent chemoradiation versus surgery (n=3 studies)
Scarce prospective data are available on the treatment of LAVC in the curative setting with primary chemoradiation without planned surgery. A systematic review specifically comparing chemoradiation in LAVC to other treatment modalities by Shylasree et al [60] included two retrospective series [46, 61] of primary chemoradiation versus primary surgery and one RCT [62] of neoadjuvant chemoraditation versus primary surgery in patients with operable disease. None of the studies showed a survival benefit for either treatment option and no differences in morbidity could be demonstrated. However, study populations are small and the RCT discussed has not been published as a full paper version. In addition, reporting of morbidity was incomplete and none of these studies include data on quality of life [60] .
Targeted Therapies
There are no published trials of targeted biological agents in LAVC. There is however one ongoing Phase II study of Pazopanib (a tyrosine kinase inhibitor and vascular endothelial growth factor inhibitor) registered with the Clinical Trials Register, which includes advanced vulval cancer as well as other gynaecological malignancies [63] .
Recurrent disease
The majority of case series and studies to date have focused upon the treatment of LAVC in the primary setting. Although some cases of recurrent disease have been included in some reports overall there is little published evidence addressing the specific needs of this group of patients.
Discussion
It would appear from the literature review, which includes our own institute's experience of anovulvectomy, that there remains a strong case for surgical management of LAVC, especially in node negative cases, with good reported disease specific survival. Our study of anovulvectomy presents the outcomes from a single institution across nearly 5 decades, wherein management policies have remained relatively unchanged. We conclude that radical anovulvectomy is at least an equivalent treatment in terms of survival with disease specific survival of 35 months (1-336). Surgery however carries with it the physical and psychological morbidity including procedure related morbidity, physical disfigurement, psychosexual sequelae and a largely unknown impact on overall quality of life.
Studies from colorectal patients with stomas suggest that the impact is less than many speculate but definitive studies of this are lacking in our cohort. The morbidity reported in this case series is modest with complications occurring in 41 (58.6%) patients and we believe that the risk of surgical complications can be reduced by good surgical technique by surgeons experienced in management of advanced vulval cancer alongside high quality peri-operative care and careful patient selection.
Given the location of many LAVCs, many patients present with pain and physical limitations. Therefore, surgery may also be indicated for rapid palliation of disabling symptoms.
The alternative approach of chemoradiation remains experimental but the data for this multimodal treatment, especially in the neoadjuvant setting has reported good survival, comparable to that of surgery, and has also been shown to result in a reduction in the rate of stoma formation. Stomas however may still be necessary in a proportion of patients. The extent of treatment related side effects are not well described, especially in those who still require surgical excision, but there is a suggestion that the combination of chemo, radiotherapy and surgery, albeit it a more conservative excision, may still result in significant morbidity and it is unclear if these cumulative treatment-related side effects result in more of an impact upon overall quality of life in comparison to stoma formation. Conversely, a proportion of patients who undergo upfront anovulvectomy with narrow resection margins or positive lymph nodes will require radiotherapy and it is unclear if this treatment order results in less morbidity and better outcomes in comparison to neoadjuvant chemoradiation.
The literature for the use of chemotherapy in the treatment of LAVC is relatively clear, confirming our concerns. In comparison to radical surgery, chemotherapy has been shown to be associated with poor survival and significant treatment related toxicity. It is our view that chemotherapy is therefore best reserved for use in the palliative setting, in patients with distant disease, or where the presence of significant co-morbidities precludes chemoradiation or surgical treatments.
The ideal alternative treatment would improve both survival and quality of life, without increasing complications and morbidity but it is clear that there is no universal recommendation that can be made for all patients. Accepting that many patients affected by LAVC are largely elderly, often with significant morbidity, many may not be suitable for all treatment modalities and therefore we still need to maintain a degree of personalisation of care. Survival outcomes should be considered alongside the associated side-effect profiles of each modality enabling appropriate treatments to be selected for each individual. However, for those patients whose treatment options are not restricted there remain many unanswered questions.
Despite a number of publications from recognised institutions, uncertainty regarding optimal treatment remains and it is unlikely that additional case series will add sufficient evidence to dictate a change in current practice. LAVC however represents a relatively small proportion of any individual institutions' caseload and it is evident that different centres have their own approach. These variations in treatment practices represents a state of clinical equipoise presenting the opportunity to explore this dilemma and answer the question of optimal treatment in a clinical trial.
To our knowledge, there are currently no plans for any randomised trials. Published series to date have supplied the baseline data necessary for such a study providing an understanding of the important clinical endpoints. It is not disputed that any RCT in this cohort of patients will have its own limitations owing to the rarity of LAVC, the complicating factors of variable tumour size, patient comorbidities and difficulties in randomisation. However, accepting that these are limitations that can be overcome through consensus we present the basis of a RCT where these factors would need to be debated.
Topics for debate include: 1) designing the control and investigational arms of an RCT. Based upon the observed good survival seen in the review of radical surgical resection, and the achievement of local disease control and symptoms, we propose radical surgery to be the standard treatment arm. In light of the promising survival outcomes achieved with chemoradiation alongside a possible reduction in the need for radical surgery including stoma formation, we recommend chemoradiation with or without additional tailored surgery for the investigational arm.
2) Sample size and feasibility. One of the greatest anxieties about an RCT in this setting is the ability to recruit adequate numbers of patients with sufficient follow-up.
A primary outcome of a modest survival difference of 5-10% between the two arms, powered to 90% with significance set at p=0.05, two tailed (as uncertainty as to which treatment would provide an improved survival) would require a sample size of approximately 500 patients, which is not unrealistic in an international setting.
Alternatively, an RCT powered to show equivalence in terms of survival with the primary outcome measures of quality of life and/or morbidity may provide a more robust assessment of these very relevant aspects but would necessitate a larger sample size. Accepting that there are numerous and complex issues to take into consideration, it is also clear that we are in a state of clinical equipoise with evidence that can be best described as conflicting, biased and inadequate. Due to the rarity of the condition and the lack of patient support groups in vulva cancer promoting and demanding better research in this cancer site it is not surprising that it features low in the priority list of most national and international research groups rendering it into a "Cinderella" status. So we should ask ourselves, is locally advanced vulvar cancer really in the "too difficult to do" box?
Conclusion
Treatment of LAVC with radical surgery, including anovulvectomy continues to be a standard of care which results in good survival outcomes and acceptable morbidity.
Neoadjuvant chemotherapy or radiotherapy alone may be best reserved for the palliative setting or metastatic disease. There is also evidence to support the alternative approach of chemoradiation as the investigational arm of a definitive RCT. Direct comparisons with the standard approach of radical surgery are required to address the uncertainty of survival outcomes, morbidity and quality of life measures between the two treatment approaches.
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Tables and Figures
Box 1 Operative Anovulvectomy Procedure
Examination under anaesthesia is performed to assess the extension of the tumour and groin node involvement.
A catheter is inserted and the patient is in a supine position. Pre-1990 a midline laparotomy was performed to assess the abdominal and pelvic cavity for metastasis and pelvic and para-aortic lymph node involvement. If palpable lymph nodes were found, a pelvic lymph node dissection was performed. This was later omitted in patients with no radiological evidence of lymphadenopathy. A permanent sigmoid end colostomy was formed, with stapling or oversewing of the distal segment of bowel. The midline laparotomy incision was later modified to a parastomal incision.
In primary diagnosed cases, bilateral groin node dissection is performed with separate linear groin incisions [2] . 
